BioSpace News Archive

Humanigen, Inc. (Nasdaq:HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine storm” with its lead drug candidate lenzilumab™, today announced that it has priced its underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $18.50 per share, resulting in gross proceeds to Humanigen

3D Medicines to Lead the Manufacture, Clinical Development and Commercialization of IMC-002 for Oncology indications in Greater China

Chinese leading biopharmaceutical company 3SBio unveiled its 2020 full-year results. The Company maintained stable profitability despite the huge challenge amid the COVID-19 pandemic, while ushering in new milestones.

Phase 2 basket trial will be conducted in patients with relapse/refractory esophageal squamous cell carcinoma, gastric cancer, and cervical cancer